I do not invest in this company, but the company made it clear they delayed their scheduled 3rd interim IDMC review so that it would coordinate with the genitourinary conference that is to begin on Thursday.
It's hard for me to imagine the IDMC did not plan to wrap up that third review by tomorrow. Actually, I'd think today would be more appropriate.
I suppose management will want a couple days before announcing it.
On Saturday, ARGOS gives a talk/poster on therapy to combat bladder cancer that moves aggressively into the muscle tissue.
Good, bad or indifferent news on the RCC trial, I'd want the bladder cancer therapy presentation to follow it in order to either highlight the next big thing if the RCC trial is a success, cushion the blow if it is not or simply prevent pesky reporters from hounding the presenter about off topic issues.
News 
Market Data 
Discover 
